RecruitingNCT05106387
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
A Noninterventional Extension Study for Patients Treated in Study R5459-RT-1944 With Vonsetamig (BCMA x CD3 Bispecific Antibody) Who Receive a Kidney Transplant
Sponsor
Regeneron Pharmaceuticals
Enrollment
20 participants
Start Date
Oct 19, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347). No study drug will be given during this study.
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria4
- Received at least 1 dose of treatment with vonsetamig in study R5459-RT-1944 \[NCT05092347\].
- Received after acceptable crossmatching, a kidney transplant while enrolled in study R5459-RT-1944
- Willing and able to comply with clinic visits and study-related procedures
- Provide informed consent signed by study patient or legally acceptable representative
Interventions
DRUGNoninterventional
No investigational treatment will be given in this noninterventional extension study
Locations(9)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05106387
Related Trials
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)
NCT069066276 locations
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)
NCT069066406 locations
An Intervention to Reduce Sedentary Behavior for Adults With Chronic Kidney Disease
NCT067542801 location
A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)
NCT0509234710 locations
Multifrequency MRE in Evaluation of Chronic Kidney Diseases
NCT062022351 location